New solid forms of [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl-[5-methanesulfonyl-2-((s)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I)

• wherein
• X—Y is CH═CH, or
• X—Y is CH2—CH2;
• A is selected from the group consisting of
• R1, R2, R3 and R4 are each independently
• hydrogen,
• halo,
• C1-6-alkyl, optionally substituted by OH
• halo-C1-6-alkyl,
• C1-6-alkoxy, optionally substituted by OH, or
• halo-C1-6alkoxy;
• R5 and R5′ are each independently hydrogen or methyl;
• R6 is hydrogen or C1-6-alkyl;
• R7 is hydrogen,
• C1-6-alkyl, optionally substituted by CN or OH, or
• —(C1-6-alkylene)-C(O)—NRaRb;
• R8 is hydrogen,
• C1-6-alkyl,
• C1-6-alkoxy,
• —(C1-6-alkylene)-NRcRd,
• —(C1-6-alkylene)-C(O)Rf,
• benzyl, optionally substituted by one or more halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, or cyano, or
• phenyl, optionally substituted by one or more halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, or cyano;
• R9 is hydrogen, halo, C1-6-alkyl, or C1-6-alkoxy;
• R10 is hydrogen, halo, C1-6-alkyl, halo-C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, or —O—C2-10-alkenyl;
• R11 is hydrogen, halo, C1-6-alkyl, or C1-6-alkoxy;
• or R10 and R11 are bound together to form a ring with the benzo moiety, wherein —R10-R11— is —O—(CH2)n—O— wherein n is 1 or 2;
• R12 is hydrogen,
• C1-6-alkyl, optionally substituted by CN or OH,
• —(C1-6-alkylene)-NRgRh,
• —(C1-6-alkylene)-C(O)—NRiRj
• —O-benzyl, optionally substituted by one or more halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, or cyano,
• nitro,
• halo,
• cyano,
• C1-6-alkoxy,
• halo-C1-6-alkoxy,
• halo-C1-6-alkyl,
• —(C1-6-alkylene)-C(O)Rf,
• phenyl, optionally substituted by one or more halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, or cyano,
• —(C1-3-alkylene)-Rm,
• wherein Rm is phenyl, a 5- to 6-membered heteroaryl, 4- to 6-membered heterocycloalkyl or 3 to 6-membered cycloalkyl,
• each optionally substituted by one or more halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, or cyano, or
• —NRnRo;
• or R11 and R12 are bound together to form a ring with the benzo moiety, wherein
• —R11-R12— is —O—(CH2)n—C(O)—,
• —C(O)—(CH2)n—O—, or
• —O—(CH2)n—O— wherein n is 1 or 2;
• Ra, Rb, Ri and Rj are each independently
• hydrogen,
• C1-6-alkyl, or
• —(C1-6-alkylene)-NRkRl,
• wherein Rk and Rl are each independently hydrogen or C1-6-alkyl,
• or Ra and Rb, or Ri and Rj together with the nitrogen to which they are bound form a five or six membered heterocycle comprising one or two heteroatoms selected from the group of nitrogen, oxygen and sulfur;
• Rc, Rd, Rg, Rh, Rn and Ro are each independently
• hydrogen,
• C1-6-alkyl, or
• —C(O)Re, or —S(O)2Re
• wherein Re is selected from the group of
• hydrogen,
• C1-6-alkyl, and
• phenyl, optionally substituted by one or more halo, halo-C1-6-alkyl,
• C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, or cyano;
• or Rc and Rd, or Rn and Ro together with the nitrogen to which they are bound form a five or six membered heterocycle comprising one or two heteroatoms selected from the group of nitrogen, oxygen and sulfur;
• Rf is selected from the group of
• hydrogen,
• C1-6-alkyl,
• C1-6-alkoxy;
• and
• phenyl, optionally substituted by one or more halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, or cyano;
• or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.